• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Where You Live Can Shape How Alzheimer ’ s Affects You
The FDA in mid-July for the first time ever approved an Alzheimer’s drug, Leqembi. The annual price-tag will run patients $26,500. The same week, the Alzheimer’s Association for the first time ever released county-level data to identify which communities are most struggling with the disease. 6.7 million Americans live with Alzheimer’s disease and 134,000 of them will die because of it each year. We’ve known these aggregate numbers for a while now, but with new data and new drugs, healthcare specialists can now better target attention and resources. [time-brightcove not-tgx=”true”] ...
Source: TIME: Health - August 7, 2023 Category: Consumer Health News Authors: Jeremy Ney Tags: Uncategorized freelance Source Type: news

On prioritising global health ' s triple crisis of sepsis, COVID-19 and antimicrobial resistance: a mixed-methods study from Malawi.
Conclusion Our analysis revealed strong relationships between in-hospital mortality and hospital case volume in hospitals treating a small number of cases. The nonlinearity and nonm onotonicity of the estimated relationships indicate that studies applying conventional statistical approaches like logistic regression should consider these relationships adequately.
Source: Current Awareness Service for Health (CASH) - December 14, 2022 Category: Consumer Health News Source Type: news

On prioritising global health ' s triple crisis of sepsis, COVID-19 and antimicrobial resistance: a mixed-methods study from Malawi
Conclusion Our analysis revealed strong relationships between in-hospital mortality and hospital case volume in hospitals treating a small number of cases. The nonlinearity and nonm onotonicity of the estimated relationships indicate that studies applying conventional statistical approaches like logistic regression should consider these relationships adequately.
Source: Current Awareness Service for Health (CASH) - December 14, 2022 Category: Consumer Health News Source Type: news

U.S. FDA Approves TECVAYLI ™ (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
HORSHAM, Pa., October 25, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) approved TECVAYLI™ (teclistamab-cqyv) for the treatment of adult patients with relapsed or refractory multiple myeloma, who previously received four or more prior lines of therapy, including a proteasome inhibitor, immunomodulatory drug and anti-CD38 monoclonal antibody.1 TECVAYLI™ is a first-in-class, bispecific T-cell engager antibody that is administered as a subcutaneous treatment.1 This off-the-shelf (or ready to use) therapy uses innovative science to ac...
Source: Johnson and Johnson - October 25, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

CT radiomics predicts esophageal cancer outcomes
Machine-learning models that assess both peritumoral and intratumoral radiomics...Read more on AuntMinnie.comRelated Reading: PET radiomics tailor head/neck cancer treatment CT radiomics can predict COVID-19 pneumonia outcomes AI, radiomics can predict stroke treatment success Can radiomics improve CT lung cancer screening? AI can predict if COVID-19 patients will need ventilators
Source: AuntMinnie.com Headlines - September 11, 2020 Category: Radiology Source Type: news

What Causes Facial Nerve Palsy?
Discussion Facial nerve palsy has been known for centuries, but in 1821 unilateral facial nerve paralysis was described by Sir Charles Bell. Bell’s palsy (BP) is a unilateral, acute facial paralysis that is clinically diagnosed after other etiologies have been excluded by appropriate history, physical examination and/or laboratory testing or imaging. Symptoms include abnormal movement of facial nerve. It can be associated with changes in facial sensation, hearing, taste or excessive tearing. The right and left sides are equally affected but bilateral BP is rare (0.3%). Paralysis can be complete or incomplete at prese...
Source: PediatricEducation.org - June 3, 2019 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

Superbugs, Anti-Vaxxers Make WHO ’ s List Of 10 Global Health Threats
(CNN) — From climate change to superbugs, the World Health Organization has laid out 10 big threats to our global health in 2019. And unless these threats get addressed, millions of lives will be in jeopardy. Here’s a snapshot of 10 urgent health issues, according to the United Nations’ public health agency: Not vaccinating when you can One of the most controversial recent health topics in the US is now an international concern. “Vaccine hesitancy — the reluctance or refusal to vaccinate despite the availability of vaccines — threatens to reverse progress made in tackling vaccine-prevent...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - January 21, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News CNN Local TV Source Type: news

High blood pressure: Why me?
“I go to the gym, and I never add salt. So why do I have high blood pressure?” Despite its astonishing prevalence of one in three Americans, many people struggle with the diagnosis of high blood pressure, or hypertension. It’s worth exploring why, because being an active participant in your care is crucial for optimal blood pressure control. Certain features make any diagnosis easier to accept: First, people are more likely to accept a diagnosis if they have symptoms. A person with cough and fever will believe a diagnosis of pneumonia. But someone who feels fine would not. Next, people more readily accept a diagnosi...
Source: New Harvard Health Information - May 2, 2016 Category: Consumer Health News Authors: Naomi D. L. Fisher, MD Tags: Behavioral Health Health care Heart Health Hypertension and Stroke Prevention Screening high blood pressure Source Type: news